Efficacy Study of RO7268489 in Animal/Cell Subjects with Progressive MS

The study aims to assess RO7268489's effectiveness as an add-on therapy to ocrelizumab in progressive multiple sclerosis (PMS) participants, following a 110-week follow-up period. This is a Phase II, double-blind, placebo-controlled trial with the primary endpoint focused on disability progression.

Tags: #MSResearch
Most relevant to: —
Source: Read original source

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

Understanding the efficacy of RO7268489 could enhance treatment strategies for progressive MS, potentially improving patient outcomes.

What this does not prove

No results are provided, and planned enrollment and endpoints do not constitute findings. The research appears to be ongoing without conclusive outcomes reported.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: Not reported
Randomised: Yes
Controlled: Yes
Primary endpoint met: Not reported
Relevant MS type: All
Publication date: Not reported
Evidence reviewed: Trial registry record
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Trial registrationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) ↗

Supporting passages (9)

study phase"briefSummary": "The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab.

randomized"briefSummary": "The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab.

controlled"officialTitle": "A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis",

relevant ms types"officialTitle": "A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis",

intervention"description": "RO7268489 will be administered per schedule as specified in the arms.",

primary endpoint"measure": "Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12)",

follow up"timeFrame": "Up to approximately 110 weeks"

findings"briefTitle": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)",

limitationsPlanned enrolment and endpoints are not findings.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.